{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:08:23Z","timestamp":1778558903761,"version":"3.51.4"},"reference-count":138,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.autrev.2022.103170","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T23:37:21Z","timestamp":1660174641000},"page":"103170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica"],"prefix":"10.1016","volume":"21","author":[{"given":"Staley A.","family":"Brod","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0015","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0020","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(08)70138-8","article-title":"Autologous haematopoietic stem-cell transplantation in multiple sclerosis","volume":"7","author":"Mancardi","year":"2008","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/1352458511429320","article-title":"Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-Centre experience","volume":"18","author":"Mancardi","year":"2012","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13311-012-0162-5","article-title":"Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned","volume":"10","author":"Atkins","year":"2013","journal-title":"Neurotherapeutics."},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/bmt.2014.251","article-title":"SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking","volume":"50","author":"Alexander","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2022.103170_bb0040","series-title":"A Quality Initiative of the Program in Evidence Based Care (PEBC), Cancer Care Ontario (CCO) Autologous Hematopoietic Cell Transplantation for Auto Immune Diseases","first-page":"35","author":"Atkins","year":"2019"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT autoimmune diseases working party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0050","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.gastro.2005.01.015","article-title":"Resetting the immune system in refractory Crohn\u2019s disease: is autologous hematopoietic stem cell transplantation the way forward?","volume":"128","author":"Barkholt","year":"2005","journal-title":"Gastroenterology."},{"issue":"10","key":"10.1016\/j.autrev.2022.103170_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4252\/wjsc.v10.i10.134","article-title":"Hematopoietic stem cell transplantation for Crohn\u2019s disease: gaps, doubts and perspectives","volume":"10","author":"Ruiz","year":"2018","journal-title":"World J Stem Cells"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1474-4422(04)00966-4","article-title":"Autologous haematopoietic-stem-cell transplantation for multiple sclerosis","volume":"4","author":"Blanco","year":"2005","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3324\/haematol.2009.017038","article-title":"Stem cell transplantation for autoimmune diseases","volume":"95","author":"Hugle","year":"2010","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0070","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24079","article-title":"Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica","volume":"75","author":"Greco","year":"2014","journal-title":"Ann Neurol"},{"issue":"10044","key":"10.1016\/j.autrev.2022.103170_bb0075","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(16)30169-6","article-title":"Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial","volume":"388","author":"Atkins","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaut.2007.12.009","article-title":"Will hematopoietic stem cell transplantation cure human autoimmune diseases?","volume":"30","author":"Marmont","year":"2008","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.autrev.2022.103170_bb0085","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0090","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol"},{"issue":"22","key":"10.1016\/j.autrev.2022.103170_bb0095","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103170_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jns.2017.01.016","article-title":"Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"373","author":"Wundes","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2022.103170_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00400414","article-title":"Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM","volume":"39","author":"Hussain","year":"1996","journal-title":"Diabetologia."},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0110","first-page":"306","article-title":"CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients","volume":"88","author":"Carreras","year":"2003","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on autoimmune diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.autrev.2022.103170_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clim.2016.06.005","article-title":"Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation","volume":"169","author":"Arruda","year":"2016","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2022.103170_bb0125","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V92.10.3505","article-title":"Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation","volume":"92","author":"Burt","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ard.2007.077446","article-title":"High-dose cyclophosphamide without stem cell rescue in scleroderma","volume":"67","author":"Tehlirian","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2022.103170_bb0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bmt.1700944","article-title":"Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study","volume":"20","author":"Fassas","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0140","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2005-06-2269","article-title":"Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin","volume":"107","author":"Zand","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-008-0132-5","article-title":"Reconstitution of the immune system after hematopoietic stem cell transplantation in humans","volume":"30","author":"Storek","year":"2008","journal-title":"Semin Immunopathol"},{"issue":"9","key":"10.1016\/j.autrev.2022.103170_bb0150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/jnnp.2007.133520","article-title":"Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis","volume":"79","author":"Mondria","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bmt.2009.139","article-title":"T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft","volume":"45","author":"Dubinsky","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0160","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/cei.12985","article-title":"Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation","volume":"189","author":"Karnell","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/imm.12129","article-title":"T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis","volume":"140","author":"Burman","year":"2013","journal-title":"Immunology."},{"issue":"Pt 9","key":"10.1016\/j.autrev.2022.103170_bb0180","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1093\/brain\/awt182","article-title":"Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis","volume":"136","author":"Abrahamsson","year":"2013","journal-title":"Brain."},{"issue":"Pt 5","key":"10.1016\/j.autrev.2022.103170_bb0185","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awh117","article-title":"Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis","volume":"127","author":"Sun","year":"2004","journal-title":"Brain."},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2015-06-649145","article-title":"Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells","volume":"127","author":"Delemarre","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103170_bb0195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2018.00410","article-title":"Regenerating Immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant","volume":"9","author":"Massey","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103170_bb0200","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3389\/fimmu.2018.00834","article-title":"Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis","volume":"9","author":"Darlington","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0205","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI71691","article-title":"T cell repertoire following autologous stem cell transplantation for multiple sclerosis","volume":"124","author":"Muraro","year":"2014","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0210","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2022.103170_bb0215","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103170_bb0220","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/eji.201444688","article-title":"PD-1 is not required for natural or peripherally induced regulatory T cells: severe autoimmunity despite normal production of regulatory T cells","volume":"44","author":"Ellestad","year":"2014","journal-title":"Eur J Immunol"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2022.103170_bb0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaut.2011.02.009","article-title":"Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis","volume":"36","author":"Thangavelu","year":"2011","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/acn3.51510","article-title":"Sustained immunotolerance in multiple sclerosis after stem cell transplant","volume":"9","author":"Visweswaran","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0240","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nri3605","article-title":"Homeostatic control of regulatory T cell diversity","volume":"14","author":"Liston","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0245","first-page":"107","article-title":"Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"64","author":"Arruda","year":"2016","journal-title":"Curr Res Transl Med"},{"issue":"10","key":"10.1016\/j.autrev.2022.103170_bb0250","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1182\/blood-2007-12-128488","article-title":"Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells","volume":"111","author":"Roord","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/CS20140095","article-title":"Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis","volume":"128","author":"de Paula","year":"2015","journal-title":"Clin Sci (Lond)"},{"issue":"9","key":"10.1016\/j.autrev.2022.103170_bb0260","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.4049\/jimmunol.0904076","article-title":"CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia","volume":"184","author":"Winstead","year":"2010","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2022.103170_bb0265","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1002\/eji.201040600","article-title":"CD4+ CD25+ Treg regulate the contribution of CD8+ T-cell subsets in repopulation of the lymphopenic environment","volume":"40","author":"Almeida","year":"2010","journal-title":"Eur J Immunol"},{"issue":"9218","key":"10.1016\/j.autrev.2022.103170_bb0270","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(00)02293-5","article-title":"Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution","volume":"355","author":"Douek","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0275","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0280","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MOT.0000000000000096","article-title":"Homeostatic expansion as a barrier to lymphocyte depletion strategies","volume":"19","author":"Zwang","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"issue":"1 Suppl","key":"10.1016\/j.autrev.2022.103170_bb0285","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.bbmt.2009.10.003","article-title":"Immune reconstitution: how it should work, what\u2019s broken, and why it matters","volume":"16","author":"Gress","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.autrev.2022.103170_bb0290","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1084\/jem.20011723","article-title":"Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection","volume":"195","author":"Reignat","year":"2002","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0295","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood.V99.7.2505","article-title":"Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS","volume":"99","author":"Kostense","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2022.103170_bb0300","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1128\/JVI.75.12.5550-5558.2001","article-title":"Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus","volume":"75","author":"Gruener","year":"2001","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0305","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/jc.2011-2188","article-title":"Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in Chinese patients with new onset of type 1 diabetes","volume":"97","author":"Li","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0310","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/art.21036","article-title":"Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis","volume":"52","author":"Farge","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2022.103170_bb0315","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.3389\/fimmu.2018.02602","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers","volume":"9","author":"Malmegrim","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0320","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2022.103170_bb0330","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2022.103170_bb0335","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/brain\/awx154","article-title":"Cell-based therapeutic strategies for multiple sclerosis","volume":"140","author":"Scolding","year":"2017","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0340","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","article-title":"Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation","volume":"25","author":"Cohen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9856","key":"10.1016\/j.autrev.2022.103170_bb0345","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.autrev.2022.103170_bb0350","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102492","article-title":"Immunological consequences of \u201cimmune reconstitution therapy\u201d in multiple sclerosis: a systematic review","volume":"19","author":"Sellner","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0360","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000194","article-title":"Alemtuzumab long-term immunologic effect: treg suppressor function increases up to 24 months","volume":"3","author":"De Mercanti","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.autrev.2022.103170_bb0365","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","article-title":"Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis","volume":"191","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2022.103170_bb0370","series-title":"Characterization of the Peripheral Blood Transcriptome in Alemtuzumab-treated Relapsing Remitting Multiple Sclerosis Patients from the CARE MS I and II Studies","author":"Zhang","year":"2019"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0375","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.autrev.2022.103170_bb0380","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2022.103170_bb0385","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jneuroim.2016.12.010","article-title":"Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE\/MS following anti-CD52 treatment","volume":"303","author":"Pant","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0390","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology."},{"issue":"1\u20132","key":"10.1016\/j.autrev.2022.103170_bb0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneuroim.2013.04.018","article-title":"Immune status following alemtuzumab treatment in human CD52 transgenic mice","volume":"261","author":"Turner","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2022.103170_bb0400","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fimmu.2019.01204","article-title":"Alemtuzumab in multiple sclerosis: short- and long-term effects of Immunodepletion on the peripheral Treg compartment","volume":"10","author":"Haas","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0405","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/imm.12696","article-title":"Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis","volume":"150","author":"von Kutzleben","year":"2017","journal-title":"Immunology."},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0410","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Cossburn","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103170_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.909275","article-title":"Innate lymphoid cells - neglected players in multiple sclerosis","volume":"13","author":"Sadeghi Hassanabadi","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0420","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000289","article-title":"Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis","volume":"3","author":"Gross","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2022.103170_bb0425","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fimmu.2012.00024","article-title":"Lymphoid tissue inducer cells: pivotal cells in the evolution of CD4 immunity and tolerance?","volume":"3","author":"Lane","year":"2012","journal-title":"Front Immunol"},{"issue":"145","key":"10.1016\/j.autrev.2022.103170_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004140","article-title":"Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis","volume":"4","author":"Perry","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"issue":"50","key":"10.1016\/j.autrev.2022.103170_bb0440","doi-asserted-by":"crossref","first-page":"20200","DOI":"10.1073\/pnas.1313654110","article-title":"Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation","volume":"110","author":"Jones","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0445","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1212\/WNL.0b013e31827b5927","article-title":"Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis","volume":"80","author":"Cossburn","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0450","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0455","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology."},{"issue":"24","key":"10.1016\/j.autrev.2022.103170_bb0460","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1212\/WNL.0000000000000520","article-title":"Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity","volume":"82","author":"Kousin-Ezewu","year":"2014","journal-title":"Neurology"},{"issue":"Pt 8","key":"10.1016\/j.autrev.2022.103170_bb0465","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/brain\/awq176","article-title":"Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity","volume":"133","author":"Jones","year":"2010","journal-title":"Brain."},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0470","article-title":"Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years","volume":"6","author":"Horakova","year":"2020","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.autrev.2022.103170_bb0475","series-title":"Alemtuzumab Maintains Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 10 Years in RRMS Patients: CARE-MS I Follow Up (Topaz Study)","author":"Coles","year":"2021"},{"key":"10.1016\/j.autrev.2022.103170_bb0480","series-title":"Early Treatment with Alemtuzumab Maintains Its Efficacy on Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, Over 10 Years in RRMS Patients: CARE-MS II Follow Up (Topaz Study)","author":"Giovannoni","year":"2021"},{"issue":"8","key":"10.1016\/j.autrev.2022.103170_bb0485","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/1352458519832259","article-title":"Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy","volume":"25","author":"Gerevini","year":"2019","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0490","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","article-title":"Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis","volume":"10","author":"Giovannoni","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2022.103170_bb0495","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419854986","article-title":"Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers","volume":"12","author":"Stuve","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2022.103170_bb0500","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2022.103170_bb0505","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0510","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","article-title":"Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system","volume":"113","author":"Alexander","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2022.103170_bb0515","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2017.00167","article-title":"Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes","volume":"8","author":"Malmegrim","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2022.103170_bb0520","series-title":"Presented at ECTRIMS","article-title":"Specific patterns in decline of immune cells upon treatment with orale cladribine","author":"Pul","year":"2019"},{"key":"10.1016\/j.autrev.2022.103170_bb0525","series-title":"Presented at: 50th Congresso Nazionale; 12\u201315 Ottobre 2019","article-title":"Changes in lymphocyte subpulations in highly active multiple sclerosis patients during cladribine treatment","author":"Ruggieri","year":"2019"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0530","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2022.103170_bb0535","series-title":"Paper Presented at ACTRIMS2019; Dallas, TX","article-title":"Durability of NEDA-3 status in patients with relapsing multiple sclerosis Receicing Cladribine tablets: CLARITY extension","author":"Giovannoni","year":"2019"},{"key":"10.1016\/j.autrev.2022.103170_bb0540","series-title":"CLARITY Extension Presented at: CMSC","article-title":"Durability of NEDA status in patients with relapsing multiple sclerosis Receicing Cladribine tablets","author":"Giovannoni","year":"2019"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0545","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2022.103170_bb0550","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2022.103170_bb0555","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"von Essen","year":"2019","journal-title":"Brain"},{"issue":"15 Supplement","key":"10.1016\/j.autrev.2022.103170_bb0560","article-title":"Interim analysis of the OBOE (ocrelizumab biomarker outcome evaluation) study in multiple sclerosis (MS) (S24.002)","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103170_bb0565","first-page":"318","article-title":"T-cell population changes and serious infection rates in the controlled periods of the pivotal phase III trials of ocrelizumab in multiple sclerosis","volume":"23","author":"Vermersch","year":"2017","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0570","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2022.103170_bb0575","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.msard.2016.01.001","article-title":"The effects of intrathecal rituximab on biomarkers in multiple sclerosis","volume":"6","author":"Topping","year":"2016","journal-title":"Mult Scler Relat Disord"},{"issue":"24","key":"10.1016\/j.autrev.2022.103170_bb0580","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103170_bb0585","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","article-title":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions","volume":"28","author":"Mealy","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0590","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2022.103170_bb0595","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.autrev.2022.103170_bb0600","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103170_bb0605","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"Pt 6","key":"10.1016\/j.autrev.2022.103170_bb0610","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain."},{"key":"10.1016\/j.autrev.2022.103170_bb0615","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2017.11.022","article-title":"Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica","volume":"384","author":"Ajmera","year":"2018","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0620","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.autrev.2022.103170_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102971","article-title":"Immune reconstitution therapy in NMOSD","volume":"52","author":"Brod","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.autrev.2022.103170_bb0630","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0635","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jocn.2015.02.007","article-title":"Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant","volume":"22","author":"Aouad","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0640","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NRL.0b013e3181b126e3","article-title":"A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation","volume":"16","author":"Peng","year":"2010","journal-title":"Neurologist."},{"key":"10.1016\/j.autrev.2022.103170_bb0645","article-title":"Plegia to walking: AHSCBMT in severe NMOSD relapse. Case report","author":"Carlisle","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0650","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/bmt.2009.305","article-title":"Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis","volume":"45","author":"Tappenden","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2022.103170_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102404","article-title":"Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America","volume":"45","author":"Burt","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0660","first-page":"366","article-title":"The cost of hematopoietic stem-cell transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"7","key":"10.1016\/j.autrev.2022.103170_bb0665","first-page":"543","article-title":"Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis","volume":"15","author":"Goldberg","year":"2009","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"10.1016\/j.autrev.2022.103170_bb0670","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3111\/13696998.2011.602444","article-title":"Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis","volume":"14","author":"O\u2019Day","year":"2011","journal-title":"J Med Econ"},{"issue":"6","key":"10.1016\/j.autrev.2022.103170_bb0675","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3111\/13696998.2012.693553","article-title":"Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States","volume":"15","author":"Lee","year":"2012","journal-title":"J Med Econ"},{"issue":"4","key":"10.1016\/j.autrev.2022.103170_bb0680","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/WNL.0b013e3182270402","article-title":"Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study","volume":"77","author":"Noyes","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2022.103170_bb0685","series-title":"Disease-Modifying Therapies for Relapsing-Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value","author":"IfCaE","year":"2017"},{"key":"10.1016\/j.autrev.2022.103170_bb0690","series-title":"CLASSIC-MS: Long-Term Efficacy in Real World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Receives Cladribine Tablets in Phase 3 Parent Trials","author":"Giovannoni","year":"2021"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997222001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:24:35Z","timestamp":1761600275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997222001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":138,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1568997222001409"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103170","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2022.103170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103170"}}